Podcasts

Episode 30 | Treatment Considerations in ALK-Positive NSCLC

Thoracic Oncology Group of Australasia podcast, hosted by: Dr Jenny Lee joined by Professor Nick Pavlakis and Lisa Briggs.

Treatment Considerations in ALK-Positive NSCLC

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014.

They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle.

Play Episode 30 | Treatment Considerations in ALK-Positive NSCLC

More Podcasts

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining
This episode is hosted by: A/Prof Steven Kao, Prof Wendy Cooper, and Prof Ben Solomon
This episode is hosted by: Dr Pei Ni Ding, Dr Samantha Bowyer, and Mr Naveed Alam.